Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.
Elena Losina, PhD
Advertisement
Elena Losina, PhD is the codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital
Articles by Elena Losina, PhD
Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.
Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
Sudden Death in HFpEF Often Preceded by Clinical Decline
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5